Tandem Diabetes Care (TNDM) Cash from Financing Activities (2013 - 2026)

Tandem Diabetes Care has reported Cash from Financing Activities for 14 years, with the latest figure at $274.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 5948.14% year-over-year to $274.2 million; the trailing twelve-month figure through Mar 2026 stood at $235.5 million (up 2476.93% YoY), and the FY2025 full-year result was -$43.4 million, down 618.31% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $274.2 million, up from $2.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $274.2 million in Q1 2026, with the low at -$39.7 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $15.3 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities tumbled 1222.88% — and 2026, when it jumped 5948.14%.
• Tandem Diabetes Care's Cash from Financing Activities stood at $6.1 million in 2022, then sank by 57.1% to $2.6 million in 2023, then retreated by 12.04% to $2.3 million in 2024, then rose by 13.12% to $2.6 million in 2025, then jumped by 10428.46% to $274.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $274.2 million (Q1 2026), $2.6 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.